Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024996064> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2024996064 endingPage "541" @default.
- W2024996064 startingPage "537" @default.
- W2024996064 abstract "Twenty patients (16 Stage D, 4 Stage C) with prostatic cancer were treated with megestrol acetate (Megace), 160 mg. daily. Of 9 previously untreated patients, 4 had partial objective regressions (average time fourteen months to date), 4 became objectively stable (average 11.5 months), and one showed objective progression of his disease on megestrol. Among 11 patients in relapse after hormonal and/or castration therapy, one showed partial objective regression for sixteen months, 8 became objectively stable for an average of 6.8 months, and 2 showed objective progression. Bone scans either improved (40 per cent) or were stable (60 per cent) in previously untreated patients who had partial objective regression or who were objectively stable on inegestrol. Serial bone scans showed progression of disease in all previously treated patients for whom this study was available. Increased prostatic acid phosphatase decreased to normal and remained within the normal range thereafter in 4 of 6 patients in the previously untreated group; plasma testosterone fell significantly in all patients over the first two months but “escaped” toward or into the normal range in many patients after,four to six months; plasma DHeA sulfate remained significantly decreased over a twelve to eighteen-month period of observation. Since megestrol appears to be effective therapy for previously untreated prostatic cancer and since it does not cause gynecoinastia, salt retention, or thromboembolism, it should be studied further as a possible first line drug in the treatment of Stage D prostatic cancer." @default.
- W2024996064 created "2016-06-24" @default.
- W2024996064 creator A5016245468 @default.
- W2024996064 creator A5025010517 @default.
- W2024996064 creator A5036650187 @default.
- W2024996064 date "1978-11-01" @default.
- W2024996064 modified "2023-10-06" @default.
- W2024996064 title "Treatment of advanced cancer of prostate with megestrol acetate" @default.
- W2024996064 cites W1981472668 @default.
- W2024996064 cites W1994405927 @default.
- W2024996064 cites W2006155322 @default.
- W2024996064 cites W2050102879 @default.
- W2024996064 cites W2055514180 @default.
- W2024996064 cites W2083073798 @default.
- W2024996064 cites W2092785508 @default.
- W2024996064 cites W2395442671 @default.
- W2024996064 cites W2433788966 @default.
- W2024996064 cites W2461711734 @default.
- W2024996064 doi "https://doi.org/10.1016/0090-4295(78)90467-3" @default.
- W2024996064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/153029" @default.
- W2024996064 hasPublicationYear "1978" @default.
- W2024996064 type Work @default.
- W2024996064 sameAs 2024996064 @default.
- W2024996064 citedByCount "68" @default.
- W2024996064 countsByYear W20249960642013 @default.
- W2024996064 countsByYear W20249960642014 @default.
- W2024996064 countsByYear W20249960642015 @default.
- W2024996064 countsByYear W20249960642022 @default.
- W2024996064 countsByYear W20249960642023 @default.
- W2024996064 crossrefType "journal-article" @default.
- W2024996064 hasAuthorship W2024996064A5016245468 @default.
- W2024996064 hasAuthorship W2024996064A5025010517 @default.
- W2024996064 hasAuthorship W2024996064A5036650187 @default.
- W2024996064 hasConcept C121608353 @default.
- W2024996064 hasConcept C126322002 @default.
- W2024996064 hasConcept C126894567 @default.
- W2024996064 hasConcept C141071460 @default.
- W2024996064 hasConcept C146357865 @default.
- W2024996064 hasConcept C151730666 @default.
- W2024996064 hasConcept C2776235491 @default.
- W2024996064 hasConcept C2779320873 @default.
- W2024996064 hasConcept C2780192828 @default.
- W2024996064 hasConcept C2780723184 @default.
- W2024996064 hasConcept C71924100 @default.
- W2024996064 hasConcept C86803240 @default.
- W2024996064 hasConcept C90924648 @default.
- W2024996064 hasConceptScore W2024996064C121608353 @default.
- W2024996064 hasConceptScore W2024996064C126322002 @default.
- W2024996064 hasConceptScore W2024996064C126894567 @default.
- W2024996064 hasConceptScore W2024996064C141071460 @default.
- W2024996064 hasConceptScore W2024996064C146357865 @default.
- W2024996064 hasConceptScore W2024996064C151730666 @default.
- W2024996064 hasConceptScore W2024996064C2776235491 @default.
- W2024996064 hasConceptScore W2024996064C2779320873 @default.
- W2024996064 hasConceptScore W2024996064C2780192828 @default.
- W2024996064 hasConceptScore W2024996064C2780723184 @default.
- W2024996064 hasConceptScore W2024996064C71924100 @default.
- W2024996064 hasConceptScore W2024996064C86803240 @default.
- W2024996064 hasConceptScore W2024996064C90924648 @default.
- W2024996064 hasIssue "5" @default.
- W2024996064 hasLocation W20249960641 @default.
- W2024996064 hasLocation W20249960642 @default.
- W2024996064 hasOpenAccess W2024996064 @default.
- W2024996064 hasPrimaryLocation W20249960641 @default.
- W2024996064 hasRelatedWork W1987458731 @default.
- W2024996064 hasRelatedWork W2051866058 @default.
- W2024996064 hasRelatedWork W2052556282 @default.
- W2024996064 hasRelatedWork W2064408249 @default.
- W2024996064 hasRelatedWork W2077459672 @default.
- W2024996064 hasRelatedWork W2080633114 @default.
- W2024996064 hasRelatedWork W2090683022 @default.
- W2024996064 hasRelatedWork W2412727001 @default.
- W2024996064 hasRelatedWork W2413630402 @default.
- W2024996064 hasRelatedWork W2434621457 @default.
- W2024996064 hasVolume "12" @default.
- W2024996064 isParatext "false" @default.
- W2024996064 isRetracted "false" @default.
- W2024996064 magId "2024996064" @default.
- W2024996064 workType "article" @default.